secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001437749-24-021876
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic licenses fungal platforms to Proliant for recombinant albumin; up to $1.5M milestones + profit share
--------------------------------------------------------------------------------

- Dyadic and Proliant Health and Biologicals partner to commercialize animal-free recombinant human serum albumin.
- Dyadic to receive up to $1.5M in milestone payments plus a share of profits from product sales.
- First product launch expected in the first half of 2025, targeting the ~$6B serum albumin market.
- Proliant will use Dyadic's fungal microbial expression platforms for production.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924021876/0001437749-24-021876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924021876/dyai20240627_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-021876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer